IRLAB Therapeutics AB (publ)

Informe acción OM:IRLAB A

Capitalización de mercado: SEK 679.5m

Salud financiera de hoja de balance de IRLAB Therapeutics

Salud financiera controles de criterios 3/6

IRLAB Therapeutics tiene un patrimonio de los accionistas total de SEK38.0M y una deuda total de SEK52.5M, lo que sitúa su ratio deuda-patrimonio en 138%. Sus activos y pasivos totales son SEK160.3M y SEK122.3M respectivamente.

Información clave

138.0%

Ratio deuda-patrimonio

SEK 52.47m

Deuda

Ratio de cobertura de interesesn/a
EfectivoSEK 90.38m
PatrimonioSEK 38.03m
Total pasivoSEK 122.26m
Activos totalesSEK 160.29m

Actualizaciones recientes sobre salud financiera

Recent updates

Is IRLAB Therapeutics (STO:IRLAB A) Using Debt Sensibly?

Oct 30
Is IRLAB Therapeutics (STO:IRLAB A) Using Debt Sensibly?

IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?

Jun 06
IRLAB Therapeutics (STO:IRLAB A) Has Debt But No Earnings; Should You Worry?

Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation

Jan 04
Here's Why We're Watching IRLAB Therapeutics' (STO:IRLAB A) Cash Burn Situation

Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely

Sep 21
Here's Why IRLAB Therapeutics (STO:IRLAB A) Must Use Its Cash Wisely

We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

Mar 18
We Think IRLAB Therapeutics (STO:IRLAB A) Needs To Drive Business Growth Carefully

IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

Dec 01
IRLAB Therapeutics (STO:IRLAB A) Is In A Good Position To Deliver On Growth Plans

We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

May 19
We Like IRLAB Therapeutics' (STO:IRLAB A) Earnings For More Than Just Statutory Profit

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Sep 11
We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

Apr 30
We're Interested To See How IRLAB Therapeutics (STO:IRLAB A) Uses Its Cash Hoard To Grow

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Mar 19
What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth

Jan 25
We Think IRLAB Therapeutics (STO:IRLAB A) Can Afford To Drive Business Growth

Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay

Dec 21
Our View On IRLAB Therapeutics' (STO:IRLAB A) CEO Pay

What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Nov 25
What Is The Ownership Structure Like For IRLAB Therapeutics AB (publ) (STO:IRLAB A)?

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (SEK102.5M) de IRLAB A no cubren sus pasivos a corto plazo (SEK117.9M).

Pasivo a largo plazo: Los activos a corto plazo de IRLAB A (SEK102.5M) superan a sus pasivos a largo plazo (SEK4.4M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: IRLAB A tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de IRLAB A ha crecido de 0% a 138% en los últimos 5 años.


Hoja de balance


Análisis de cash runway

En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.

Cash runway estable: IRLAB A tiene suficiente cash runway para más de un año basándose en su flujo de caja libre actual.

Pronóstico de cash runway: Datos insuficientes para determinar si IRLAB A tiene suficiente cash runway en caso de que su flujo de caja libre siga creciendo o disminuyendo basado en tasas históricas.


Descubre empresas con salud financiera